Literature DB >> 12761809

Crystal forms of LY334370 HCl: isolation, solid-state characterization, and physicochemical properties.

Susan M Reutzel-Edens1, Rita L Kleemann, Peggy L Lewellen, Alfio L Borghese, Luc J Antoine.   

Abstract

LY334370 HCl, a 5HT1f agonist investigated for the treatment of migraines, was identified in five crystal forms: three anhydrates (I-III), a dihydrate, and an acetic acid solvate. The identification and characterization of these crystal forms by optical microscopy, differential scanning calorimetry, thermogravimetric and moisture sorption analyses, solid-state NMR spectroscopy, and X-ray crystallography (Form I only) are presented. Physical properties, including hygroscopicity, solubility, and intrinsic dissolution rate, were assessed for Form I and the dihydrate, the two most viable crystal forms for commercial development. Surprisingly, anhydrous Form I was found to be the thermodynamically most stable crystal form in water, dissolving six times slower than the dihydrate, a difference that correlates well with the rank order of aqueous solubility. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761809     DOI: 10.1002/jps.10373

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Effect of polymer additives on the transformation of BMS-566394 anhydrate to the dihydrate form.

Authors:  S Betigeri; A Thakur; R Shukla; K Raghavan
Journal:  Pharm Res       Date:  2007-10-12       Impact factor: 4.200

2.  Navigating the Waters of Unconventional Crystalline Hydrates.

Authors:  Doris E Braun; Lien H Koztecki; Jennifer A McMahon; Sarah L Price; Susan M Reutzel-Edens
Journal:  Mol Pharm       Date:  2015-06-30       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.